Genmab

US · GMAB #860 by market cap Listed 2019

36.65 -1.15 -3.04%

Live - 5344 symbols - heartbeat 251s ago · 2026-10-08 07:00

Pre-market 35.76 -2.43%

After-hours 36.65 0.00%

Overnight 35.73 -2.51%

Market cap: 22.54B
P/E (TTM): 28.97
P/B: 3.78
EPS: 1.54
Div yield: 0.00%
52W pos: 79%

Reader sentiment Are you bullish or bearish on GMAB?

Anonymous reader poll. Unscientific, not investment advice.

About Genmab

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Founded: 1998
CEO: Dr. Jan G. J. van de Winkel, PhD
Employees: 2,819
Headquarters: Copenhagen, Central Denmark, Denmark
Fiscal year end: 12-31
Website: genmab.com

Company profile

Exchange: US
Symbol: GMAB
Market-cap rank: #860
Listing date: 2019-07-18
Market cap: 22.54B
Float cap: 21.10B
Shares out: 614.90M
Float shares: 575.61M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.